Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/39580| Título : | CAP—advancing the evaluation of preclinical Alzheimer disease treatments |
| Autor : | Lopera Restrepo, Francisco Javier Langbaum, Jessica B. Tariot, Pierre N. Reiman, Eric M. Bateman, Randall J. Morris, John C. Sperling, Reisa A. Aisen, Paul S. Roses, Allen D. Welsh Bohmer, Kathleen A. Carrillo, Maria C. Weninger, Stacie |
| metadata.dc.subject.*: | Anciano de 80 o más Años Aged, 80 and over Enfermedad de Alzheimer Alzheimer Disease Farmacoterapia Drug Therapy Diagnóstico Diagnosis Genética Genetics Disfunción Cognitiva Cognitive Dysfunction Conducta Cooperativa Cooperative Behavior Progresión de la Enfermedad Disease Progression Evaluación Preclínica de Medicamentos Drug Evaluation, Preclinical Diagnóstico Precoz Early Diagnosis Adhesión a Directriz Guideline Adherence Comunicación Interdisciplinaria Interdisciplinary Communication Pruebas Neuropsicológicas Neuropsychological Tests Nootrópicos Nootropic Agents Síntomas Prodrómicos Prodromal Symptoms Ensayos Clínicos Controlados Aleatorios como Asunto Randomized Controlled Trials as Topic Resultado del Tratamiento Treatment Outcome https://id.nlm.nih.gov/mesh/D000369 https://id.nlm.nih.gov/mesh/D000544 https://id.nlm.nih.gov/mesh/D004358 https://id.nlm.nih.gov/mesh/D003933 https://id.nlm.nih.gov/mesh/D005823 https://id.nlm.nih.gov/mesh/D060825 https://id.nlm.nih.gov/mesh/D003299 https://id.nlm.nih.gov/mesh/D018450 https://id.nlm.nih.gov/mesh/D004353 https://id.nlm.nih.gov/mesh/D042241 https://id.nlm.nih.gov/mesh/D019983 https://id.nlm.nih.gov/mesh/D033183 https://id.nlm.nih.gov/mesh/D009483 https://id.nlm.nih.gov/mesh/D018697 https://id.nlm.nih.gov/mesh/D062706 https://id.nlm.nih.gov/mesh/D016032 https://id.nlm.nih.gov/mesh/D016896 |
| Fecha de publicación : | 2016 |
| Editorial : | Nature Research |
| Resumen : | ABSTRACT: If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials. |
| metadata.dc.identifier.eissn: | 1759-4766 |
| ISSN : | 1759-4758 |
| metadata.dc.identifier.doi: | 10.1038/nrneurol.2015.177 |
| Aparece en las colecciones: | Artículos de Revista en Ciencias Médicas |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| LoperaFrancisco_2016_CAP-Advancing.pdf | Artículo de revisión | 121.21 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons
